AbbVie (ABBV) Receivables (2012 - 2026)
AbbVie (ABBV) posted quarterly Receivables of $12.5 billion for Q1 2026, little changed year-over-year from $12.5 billion in Q1 2025, and down 0.87% quarter-over-quarter from $12.6 billion in Q4 2025.
AbbVie (ABBV) Receivables (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has reported Receivables for 15 consecutive years, with $12.5 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Receivables changed 0.02% year-over-year to $12.5 billion; the TTM figure through Mar 2026 stood at $12.5 billion (changed 0.02% YoY), while the FY2025 annual figure was $12.6 billion, up 15.29% from the prior year.
- Receivables declined to $12.5 billion in Q1 2026 per ABBV's latest filing, from $12.6 billion in the prior quarter.
- Across five years, Receivables topped out at $12.8 billion in Q3 2025 and bottomed at $10.7 billion in Q1 2022.
- Historically, Receivables has averaged $11.7 billion across 5 years, with a median of $11.5 billion in 2023.
- Annual changes were most pronounced in 2022 — Receivables increased 15.75% — and 2024, when it decreased 2.12%.
- AbbVie's Receivables stood at $11.3 billion in 2022, then retreated by 0.88% to $11.2 billion in 2023, then dropped by 2.12% to $10.9 billion in 2024, then grew by 15.29% to $12.6 billion in 2025, then slipped by 0.87% to $12.5 billion in 2026.
- Business Quant data shows ABBV's Receivables at $12.5 billion in Q1 2026, $12.6 billion in Q4 2025, and $12.8 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.88 Bn | 625.12 Bn | 17.26 Bn | 19.05 Bn |
| 2 | AbbVie | 463.46 Bn | 456.89 Bn | 12.70 Bn | 13.82 Bn |
| 3 | Merck | 367.92 Bn | 360.78 Bn | 12.21 Bn | 12.56 Bn |
| 4 | Novartis Ag | 297.71 Bn | 290.02 Bn | 11.24 Bn | 9.64 Bn |
| 5 | Astrazeneca | 255.55 Bn | 250.65 Bn | 12.86 Bn | 14.33 Bn |
| 6 | Amgen | 234.52 Bn | 220.53 Bn | 7.24 Bn | 10.23 Bn |
| 7 | Gilead Sciences | 178.22 Bn | 175.04 Bn | 6.22 Bn | 5.90 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 12.49 Bn |
| 9 | Gsk | 105.32 Bn | 101.15 Bn | 8.24 Bn | 10.34 Bn |
| 10 | Sanofi | 54.20 Bn | 46.82 Bn | 10.79 Bn | 10.13 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 13.82 Bn |
| Mar 31, 2026 | 12.48 Bn |
| Dec 31, 2025 | 12.59 Bn |
| Sep 30, 2025 | 12.77 Bn |
| Jun 30, 2025 | 12.64 Bn |
| Mar 31, 2025 | 12.48 Bn |
| Dec 31, 2024 | 10.92 Bn |
| Sep 30, 2024 | 11.47 Bn |
| Jun 30, 2024 | 11.72 Bn |
| Mar 31, 2024 | 11.95 Bn |
| Dec 31, 2023 | 11.16 Bn |
| Sep 30, 2023 | 11.41 Bn |
| Jun 30, 2023 | 11.49 Bn |
| Mar 31, 2023 | 11.47 Bn |
| Dec 31, 2022 | 11.25 Bn |
| Sep 30, 2022 | 10.74 Bn |
| Jun 30, 2022 | 11.24 Bn |
| Mar 31, 2022 | 10.73 Bn |
| Dec 31, 2021 | 9.98 Bn |
| Sep 30, 2021 | 9.28 Bn |